It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...

Operatives working for Elon Musk’s DOGE appear to be editing the code of AutoRIF—software designed by the Defense Department ...

The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...